Frequency Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.4301
- Today's High:
- $0.44
- Open Price:
- $0.44
- 52W Low:
- $0.326
- 52W High:
- $5.59
- Prev. Close:
- $0.439
- Volume:
- 18851
Company Statistics
- Market Cap.:
- $17.02 million
- Book Value:
- 1.263
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-42015000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -35.63%
- Return on Equity TTM:
- -95.21%
Company Profile
Frequency Therapeutics Inc had its IPO on 2019-10-03 under the ticker symbol FREQ.
The company operates in the Healthcare sector and Biotechnology industry. Frequency Therapeutics Inc has a staff strength of 46 employees.
Stock update
Shares of Frequency Therapeutics Inc opened at $0.44 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.43 - $0.44, and closed at $0.43.
This is a -2.03% slip from the previous day's closing price.
A total volume of 18,851 shares were traded at the close of the day’s session.
In the last one week, shares of Frequency Therapeutics Inc have slipped by -7.7%.
Frequency Therapeutics Inc's Key Ratios
Frequency Therapeutics Inc has a market cap of $17.02 million, indicating a price to book ratio of 0.9077 and a price to sales ratio of 7.5026.
In the last 12-months Frequency Therapeutics Inc’s revenue was $0 with a gross profit of $-42015000 and an EBITDA of $-62439000. The EBITDA ratio measures Frequency Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Frequency Therapeutics Inc’s operating margin was 0% while its return on assets stood at -35.63% with a return of equity of -95.21%.
In Q2, Frequency Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Frequency Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.84 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Frequency Therapeutics Inc’s profitability.
Frequency Therapeutics Inc stock is trading at a EV to sales ratio of 0.0983 and a EV to EBITDA ratio of -0.2351. Its price to sales ratio in the trailing 12-months stood at 7.5026.
Frequency Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $79.38 million
- Total Liabilities
- $8.33 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Frequency Therapeutics Inc ended 2024 with $79.38 million in total assets and $0 in total liabilities. Its intangible assets were valued at $79.38 million while shareholder equity stood at $45.41 million.
Frequency Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $8.33 million in other current liabilities, 36000.00 in common stock, $-292004000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $39.71 million and cash and short-term investments were $46.48 million. The company’s total short-term debt was $2,163,000 while long-term debt stood at $0.
Frequency Therapeutics Inc’s total current assets stands at $48.38 million while long-term investments were $0 and short-term investments were $6.77 million. Its net receivables were $0 compared to accounts payable of $1.29 million and inventory worth $0.
In 2024, Frequency Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Frequency Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.43
- 52-Week High
- $5.59
- 52-Week Low
- $0.326
- Analyst Target Price
- $4
Frequency Therapeutics Inc stock is currently trading at $0.43 per share. It touched a 52-week high of $5.59 and a 52-week low of $5.59. Analysts tracking the stock have a 12-month average target price of $4.
Its 50-day moving average was $0.53 and 200-day moving average was $1.25 The short ratio stood at 0.88 indicating a short percent outstanding of 0%.
Around 726.9% of the company’s stock are held by insiders while 1412.1% are held by institutions.
Frequently Asked Questions About Frequency Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person’s innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company’s lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.